Selecta Biosciences to Present New Data for the ImmTOR™ platform at the ESGCT 28th Annual Congress
October 13, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for Patients with Lysosomal Storage Disorders
October 04, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference
September 21, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer
September 20, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins
September 08, 2021 08:00 ET
|
Selecta Biosciences, Inc.
- First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions- -Preclinical...
Selecta Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
August 12, 2021 08:00 ET
|
Selecta Biosciences, Inc.
IND filing for wholly owned gene therapy program, SEL-302 (MMA-101, in combination with ImmTOR) in methylmalonic acidemia (MMA) expected during the third quarter of 2021; Manufacturing issue has been...
Selecta Biosciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
August 05, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences to Participate in Upcoming Investor Conferences
August 02, 2021 08:00 ET
|
Selecta Biosciences, Inc.
WATERTOWN, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic...
Selecta Biosciences Announces Appointment of Jude Samulski, Ph.D. as Gene Therapy Special Advisor and the Publication of Data Evaluating ImmTOR™ with AAV vectors for the treatment of Methylmalonic Acidemia
July 26, 2021 08:00 ET
|
Selecta Biosciences, Inc.
– Selecta appoints gene therapy pioneer Jude Samulski, Ph.D. as a special advisor to help guide Selecta’s gene therapy programs into the clinic – – Data demonstrate that ImmTOR enhances transgene...